What sense does step therapy make for someone with severe osteoporosis since the other drugs don’t build bone

The short version: step therapy forces you to try drugs that only slow bone loss before letting you access a drug that builds new bone, and the evidence shows the builder prevents more fractures.

The VERO trial directly compared teriparatide (a bone-builder) to risedronate (a bisphosphonate that only slows breakdown) in women with severe osteoporosis. Over 24 months, teriparatide cut new vertebral fractures by more than half: about 5 in 100 women on teriparatide fractured versus 12 in 100 on risedronate [1]. The number needed to treat was 15, meaning for every 15 women given teriparatide instead of risedronate, one additional vertebral fracture was prevented [1]. Non-vertebral fractures were also lower with teriparatide, though that difference did not reach statistical significance [1]. A separate Chinese trial found teriparatide reduced new fractures by about 47% compared to alendronate, another bisphosphonate [2].

The logic of step therapy is cost control, not biology. Bisphosphonates are cheap generics; teriparatide is expensive. But for someone with severe osteoporosis—already fractured, very low bone density—the mechanism matters. Bisphosphonates freeze bone remodeling. Teriparatide stimulates new bone formation on bone surfaces [2]. The VERO trial shows that difference translates into real fracture reduction [1]. The 2020 Endocrine Society guideline, cited in a retrieved review, recommends anabolic therapy first for the highest-risk patients, followed by an antiresorptive to maintain gains [3].

The risk of delaying anabolic therapy is a fracture that could have been prevented. The VERO trial enrolled women with severe disease and showed the benefit within two years [1]. A patient who fractures while failing a bisphosphonate has already lost that window. The evidence does not support step therapy for severe osteoporosis; it supports starting with the drug that builds bone.

My call: step therapy makes no sense for severe osteoporosis because the drugs it forces you to try first do not build bone, and the trial that compared them directly showed the bone-builder prevents more fractures. Confidence: high.